Helicobacter pylori (H. pylori) infection induces methylation silencing of tumor suppressor genes causing gastric carcinogenesis. Impairment of autophagy induces DNA damage leading to genetic instability and carcinogenesis. We aimed to identify whether H. pylori infection induced methylation silencing of host autophagy-related (Atg) genes, impairing autophagy and enhancing gastric carcinogenesis. Gastric mucosae were obtained from 41 gastric cancer patients and 11 healthy volunteers (8 H. pylori-uninfected and 3 H. pylori-infected). Methylation status of Atg genes was analyzed by a methylation microarray and quantitative methylation-specific PCR (qMSP); mRNA expression was assessed by quantitative reverse transcription PCR (qRT-PCR). Cell proliferation, migration and invasion were assessed in normal rat gastric epithelial cells. Gene knock-down was performed by siRNA. Autophagy was assessed by western blotting. Of 34 Atg genes, MAP1LC3A variant 1 (MAP1LC3Av1) and ULK2 were identified by methylation microarray analysis as exhibiting specific methylation in H. pylori-infected mucosae and gastric cancer tissues. Methylation silencing of MAP1LC3Av1 was confirmed by qMSP, qRT-PCR and de-methylation treatment in two gastric cancer cell lines. Knock-down of map1lc3a, the rat homolog of the human MAP1LC3Av1, inhibited autophagy response and increased cell proliferation, migration and invasion in normal rat gastric epithelial cells, despite the presence of map1lc3b, the rat homolog of the human MAP1LC3B gene important for autophagy. Furthermore, MAP1LC3Av1 was methylation-silenced in 23.3% of gastric cancerous mucosae and 40% of non-cancerous mucosae with H. pylori infection. MAP1LC3Av1 is essential for autophagy and H. pylori-induced methylation silencing of MAP1LC3Av1 may impair autophagy, facilitating gastric carcinogenesis.
Helicobacter pylori (H. pylori) infection induces methylation silencing of tumor suppressor genes causing gastric carcinogenesis. Impairment of autophagy induces DNA damage leading to genetic instability and carcinogenesis. We aimed to identify whether H. pylori infection induced methylation silencing of host autophagy-related (Atg) genes, impairing autophagy and enhancing gastric carcinogenesis. Gastric mucosae were obtained from 41 gastric cancer patients and 11 healthy volunteers (8 H. pylori-uninfected and 3 H. pylori-infected). Methylation status of Atg genes was analyzed by a methylation microarray and quantitative methylation-specific PCR (qMSP); mRNA expression was assessed by quantitative reverse transcription PCR (qRT-PCR). Cell proliferation, migration and invasion were assessed in normal rat gastric epithelial cells. Gene knock-down was performed by siRNA. Autophagy was assessed by western blotting. Of 34 Atg genes, MAP1LC3A variant 1 (MAP1LC3Av1) and ULK2 were identified by methylation microarray analysis as exhibiting specific methylation in H. pylori-infected mucosae and gastric cancer tissues. Methylation silencing of MAP1LC3Av1 was confirmed by qMSP, qRT-PCR and de-methylation treatment in two gastric cancer cell lines. Knock-down of map1lc3a, the rat homolog of the human MAP1LC3Av1, inhibited autophagy response and increased cell proliferation, migration and invasion in normal rat gastric epithelial cells, despite the presence of map1lc3b, the rat homolog of the human MAP1LC3B gene important for autophagy. Furthermore, MAP1LC3Av1 was methylation-silenced in 23.3% of gastric cancerous mucosae and 40% of non-cancerous mucosae with H. pylori infection. MAP1LC3Av1 is essential for autophagy and H. pylori-induced methylation silencing of MAP1LC3Av1 may impair autophagy, facilitating gastric carcinogenesis.
Gastric cancer is one of the most common cancers worldwide and is among the top three leading causes of cancer-related deaths. 1, 2 Compelling evidence links Helicobacter pylori (H. pylori) infection to the initiation of a sequence of events that lead from chronic active gastritis to atrophic gastritis, intestinal metaplasia, dysplasia and finally gastric adenocarcinoma. [3] [4] [5] Several factors, such as nitric oxide, signal transducer and activator of transcription 3 and nuclear factor-jB, have been reported to be responsible for the development of H. pylori-associated gastric cancer 6, 7 ; however, the exact mechanism whereby H. pylori induces gastric carcinogenesis is not fully understood.
Additionally, H. pylori infection can cause carcinogenesis by inducing epigenetic alterations such as DNA methylation in CpG islands (CGI) of various host gene promoters, leading to silencing of the corresponding genes. 8 So far, several tumor suppressor genes and miRNAs have been reported to be silenced by H. pylori-induced DNA methylation in both H. pylori-infected cancerous and non-cancerous gastric mucosae. [8] [9] [10] [11] [12] Hence, the accumulation of such methylationsilenced genes in H. pylori-infected gastric mucosae, known as epigenetic field defects, may contribute to the development of gastric cancer. 12, 13 Autophagy is a homeostatic process that involves sequestration of cytoplasmic components in autophagosomes, which then fuse with lysosomes, leading to degradation and recycling of these components. Autophagy is regulated by the interplay between various autophagy-related (Atg) genes and protein complexes. H. pylori itself and H. pylori-induced cytokines, such as TNFa and IL6, 14, 15 are also known to induce autophagy. [16] [17] [18] Intracellular vacuolating cytotoxin A is thought to be associated with autophagosomes as co-localizing with LC-3. 18 H. pylori elicits a strong immune response; attracting neutrophils, macrophages, dendritic cells and lymphocytes, and stimulating the release of inflammatory cytokines. Subsequently, these cytokines induce intracellular autophagy. 19, 20 During infection, autophagy assists in the host immune response by degrading intracellular bacteria. 21 Although H. pylori infection is an inducer of autophagy, it may also disrupt autophagy in gastric epithelial cells and can persist the infection. 22 When autophagy is impaired by various factors, it favors the intracellular replication and survival of H. pylori in the stomach. [22] [23] [24] A defect in autophagy favors accumulation of ubiquitylated protein, dysfunctional mitochondria and increased peroxisomes and lipid droplets. 23 Such a defect increases levels of reactive oxygen species, causing chronic cellular damage. Furthermore, autophagy impairment also causes host genetic instability by activating the DNA damage response and facilitating the acquisition of genomic mutations that contribute to tumorigenesis. 25 Because H. pylori has the potential to modulate the autophagy pathway in gastric epithelial cells, H. pylori-infected cells with impaired autophagy are susceptible to the accumulation of genotoxic products. 22 Therefore, autophagy impairment by H. pylori infection is considered to be an important early step in gastric carcinogenesis. The microtubule-associated protein 1 light chain 3 (MAP1LC3/LC3) is a major regulator of autophagosome formation. Conversion of a cytosolic truncated form of LC3 (LC3-I) to its autophagosomal membrane-associated, phosphatidylethanolamine-conjugated form (LC3-II) is an indicator of autophagosome formation. 26 This conversion can be detected by western blotting and is the most widely used for monitoring autophagy. 27 In human, the LC3 proteins are encoded by members of the MAP1LC3 gene family, which consists of five genes (MAP1LC3A variant1 (MAP1LC3Av1), MAP1LC3A variant2 (MAP1LC3Av2), MAP1LC3B, MAP1LC3B2 and MAP1LC3C). Of these five genes, MAP1LC3B is known to be a major gene for autophagy. 28 Recently, MAP1LC3Av1 was found to be inactivated in various cancer cell lines and clinical esophageal squamous cell carcinoma tissues due to aberrant DNA methylation induced by unknown factors. 29 However, the role of H. pylori-induced epigenetic changes of Atg genes, such as MAP1L-C3Av1, in gastric carcinogenesis had not yet been identified. We hypothesized that H. pylori-induced methylation silencing of Atg genes in gastric epithelial cells can disrupt the autophagy pathway, thereby leading to the development of gastric cancer.
In this study, we showed that MAP1LC3Av1 was specifically methylation-silenced in H. pylori-infected non-cancerous and cancerous gastric mucosae. In addition, we demonstrated that the inactivation of map1lc3a, a rat homolog of the human MAP1LC3Av1, disrupts the autophagy pathway, thereby leading to carcinogenesis in gastric epithelial cells.
Methods

Cell lines, culture conditions and clinical tissue samples
The AGS and MKN45 cell lines (ATCC, Manassas, VA) were used. Each of these cell lines were authenticated by National Institute of Biomedical Innovation, Osaka, Japan as identical to the corresponding cell line registered in the Japanese Collection of Research Bio-resources Cell Bank database. Three separate RGE cell lines (RGE 1-21, 1-03 and 1-01) were used, conditionally immortalized normal gastric epithelial cells developed from a transgenic rat. 30 Gastric mucosae were obtained by endoscopic biopsy from a total of 11 healthy What's new? Helicobacter pylori infection has been shown to induce methylation silencing of tumor suppressor genes, causing gastric carcinogenesis. On the other side, impairment of autophagy induces DNA damage, leading to genetic instability and carcinogenesis. Here, the authors show that the host autophagy-related gene MAP1LC3Av1 is specifically methylation-silenced in H. pylori-infected non-cancerous and cancerous gastric mucosae. Inactivation of map1lc3a, a rat homolog of the human MAP1L-C3Av1, disrupts the autophagy pathway, leading to carcinogenesis in gastric epithelial cells. MAP1LC3Av1 methylation and expression levels could potentially be used as an early indicator of carcinogenic transformation of non-cancerous mucosae in H. pylori-infected gastric cancer patients.
volunteers, including 8 H. pylori-uninfected subjects and 3 H. pylori-infected patients. For reverse transcription (RT)-PCR and quantitative methylation-specific PCR (qMSP), gastric cancer tissues and their corresponding non-cancerous tissues were obtained from 30 H. pylori-infected gastric cancer patients. For the methylation microarray experiment, gastric cancerous tissues were obtained from another 11 H. pylori-infected gastric cancer patients. Written informed consent was obtained from each subject. Gastric mucosae were frozen in RNA later (Ambion, Austin, TX) immediately after biopsy and stored at 2808C. Genomic DNA (gDNA) and mRNA were extracted by the phenol-chloroform method or using an AllPrep DNA/RNA Mini Kit (Qiagen, Venlo, Limburg, Netherlands).
Human DNA methylation microarray analysis
Genome-wide DNA methylation analysis was performed on clinical samples using the Infinium HumanMethylation450 BeadChip microarray system (Illumina, San Diego, CA) as described previously. 31 The methylation status of each CpG site was represented by a b value, which ranged from 0 (completely un-methylated) to 1 (completely methylated). To analyze the presence of CGI at 200 base pairs upstream from the transcription start site (TSS200) of Atg genes, we used a public database available via the University of California Santa Cruz Genome Browser (http://genome.ucsc.edu/) on GRCh38/hg38 assembly (Genome Reference Consortium).
Methylation-specific polymerase chain reaction (MSP), quantitative MSP (qMSP) and de-methylation treatment An aliquot (1 lg) of gDNA digested using BamHI was treated with sodium bisulfite and suspended in 20 ll of TE buffer as described previously. 32 MSP and qMSP were conducted using 1 ll of the sodium bisulfite-treated DNA, primers designed for methylated and un-methylated DNA and Alu repeat sequence (Supporting Information Table 1) as described previously. 9 DNA methylation levels and percentage of methylated reference were calculated as described previously. 33, 34 De-methylation treatment was performed using 1.0 lM 5-aza-2 0 -deoxycitidine (5-Aza-dC) as described previously. 8 
Quantitative real-time RT-PCR
RT-PCR was performed using 1 ll of complementary DNA (cDNA), specific primers (Supporting Information Table 2 ), SYBRV R Green I and an iCycler Thermal Cycler. cDNA was synthesized from 1 lg of total RNA using the QuantiTect Reverse Transcription Kit (Qiagen) according to the manufacturer's protocol. Expression levels of target human genes were normalized to GAPDH expression; expression levels of target rat genes were normalized to Ppia expression.
RNA interference
The small interfering RNA (siRNA) for knock-down of MAP1LC3A/map1lc3a (siLC3A) was purchased from Cell Signaling Technology (Danvers, MA). The reverse transfection method was used to perform high-throughput transfection. Lipofectamine 2000 and Opti-MEM Reduced Serum Medium (Life Technologies, Carlsbad, CA) were used to transfect siLC3A at a final concentration of 100 nM into RGE cells. Stealth RNAi (Life Technologies) was used as a negative control.
Cell proliferation assay
Cell proliferation was evaluated by the Cell Counting Kit-8 (CCK-8) (Dojindo, Rockville, MD) according to the manufacturer's instructions and as described previously. 35 Cells were in the starved conditions without fetal bovine serum (FBS).
Wound-healing assay
Wound-healing assay was performed as described previously. 36 Cells were in the starved conditions without FBS. Results are presented as changes in wound width after a particular time interval.
Trans-well migration assay
Trans-well migration assay was performed using 12 well trans-well permeable supports with 8 lm pores (Corning, Corning, NY) according to the protocol provided by Corning Life Sciences (http://www.level.com.tw/html/ezcatfiles/vipweb20/img/img/34961/2-2an_Chemotaxis_protocol.pdf). Mixtures of RGE 1-01 cells and siRNAs were added into the top chambers of trans-well inserts. Cells were in the starved conditions without FBS. The number of cells migrated into the bottom chamber were counted. Data are presented as the mean number of cells that migrated in each well.
Matrigel invasion assay
Matrigel invasion assay was performed using 12 well transwell permeable supports with 8 lm pores (Corning), and BD Matrigel matrix (BD Biosciences, Billerica, MA) was used as an extracellular matrix to coat the topside of the trans-well inserts. The assay was performed according to the protocol by Corning Life Sciences (see the link in the previous section). Cells were in the starved conditions without FBS. The cells on the bottom side of the membrane were stained using Diff-Quick dyes (Mitsubishi Chemical Holding Corporation, Tokyo, Japan), and cells invaded to the bottom side of the membrane were counted using phase-contrast microscopy.
Western blotting analysis of LC3 and SQSTM1
To evaluate the effect of inflammatory cytokines on autophagy, RGE 1-01 cells were stimulated with TNFa (25 ng/ml) and IL6 (100 ng/ml) (R & D Systems, Minneapolis, MN) for various time course experiments. Later, in order to analyze additive effect of H. pylori infection and the cytokines, RGE 1-01 cells were co-stimulated for equal time duration with H. pylori, TNFa and/or IL6. To evaluate the role of LC3 in H. pylori-induced autophagy, LC3 knock-down RGE cells were infected with H. pylori for 8 hrs. Whole-cell lysates were prepared and western blotting was performed as described previously. 37 Primary antibodies against LC3A, LC3B and SQSTM1 were purchased from Sigma-Aldrich Corporation (St. Louis, MO). And antibody against Actin (C-11) was purchased from Santa Cruz Biotechnologies (Santa Cruz, CA). Primary antibodies were detected with horseradish peroxidase-conjugated anti-rabbit or anti-goat immunoglobulin G (Dako, Carpinteria, CA) and then visualized with ImageQuant LAS4000 (GE Healthcare, Little Chalfont, Buckinghamshire, UK). Some antibody reactions were conducted in Can Get Signal solution (Toyobo corp., Osaka, Japan) or using Blockase (DS Pharma Biomedical, Osaka, Japan).
Immunohistochemistry and confocal microscopy
Formalin-fixed, paraffin-embedded human gastric tissues were prepared from tissue-matched H. pylori-infected gastric non-cancerous and cancerous mucosae from a given patient. Sample slides were de-paraffinized with xylene, then rehydrated in ethanol. After antigen retrieval, slides were blocked with 5% bovine serum albumin for 60 min at room temperature. Sections then were incubated with primary antibody against LC3A (1:500) overnight at 48C. The bound antibody was visualized using green fluorescence-labeled secondary antibody (Alexa 488 Fluor, Life Technologies), and the section was counterstained using 4,6-diamidino-2-phenylindole. Immunofluorescence was analyzed with a LSM 700 confocal microscope (Zeiss, Jena, Germany).
Statistical analysis
Student's t test was used to evaluate the significance of differences between groups and between samples; Microsoft Excel 2010 (Microsoft Office, 2010) was used for all statistical calculations. At least three independent replicates were assessed in each experiment, and pooled data are presented as mean 6 standard error. Quantification analysis of western blotting data was performed using ImageJ software. A p values of <0.01 was considered significant. For western blotting and immunofluorescence, data presented as one representative figure from each of three independent experiments.
Results
Isolation of Atg genes specifically methylated in H. pyloriinfected non-cancerous mucosae and gastric cancers Thirty-four previously identified Atg genes 38 were analyzed in the present study (Supporting Information Table 3 ). Atg4c, Atg9b, MAP1LC3Av2, MAP1LC3B2, MAP1LC3C and PIK3C3 were excluded due to the lacks of CGIs in their promoter regions. Of the remaining 28 Atg genes, probes for use with HumanMethylation450K (Illumina) were available for analysis of CGIs in the promoters of 25 genes, the exceptions being Atg2b, PIK3R4 and ULK1. Genes that were methylated in gastric cancer and in H. pylori-infected non-cancerous mucosae were selected using the following criteria: (A) b value of H. pylori-infected non-cancerous mucosae exceeded that of uninfected mucosae by 0.2 or more, and (B) b value in at least one out of 11 gastric cancers was > 0.2. The b value of H. pylori-infected and H. pylori-uninfected mucosae was calculated as the mean of three samples in each group. MAP1LC3Av1 and ULK2 were identified based on these criteria (Fig. 1a) .
Methylation silencing of MAP1LC3Av1 in human gastric cancer cell lines
Methylation silencing of MAP1LC3Av1 and ULK2, along with that of three un-evaluated genes (Atg2b, PIK3R4 and ULK1) was evaluated in the AGS and MKN45 human gastric cancer cell lines. MAP1LC3Av1 was silenced and almost fully methylated in the both cell lines; ULK2 was methylated and silenced only in AGS (Figs. 1b and 1c) . In contrast, the other three Atg genes were expressed at variable levels and were completely un-methylated in the both cell lines. These results suggested that MAP1LC3Av1 was methylation-silenced in the both gastric cancer cell lines, and ULK2 was methylationsilenced only in AGS. ULK1 is a homolog of ULK2 and has been shown to partially compensate for the functional loss of ULK2 in the regulation of autophagy. 39 Therefore, we set aside ULK2 and focused on MAP1LC3Av1 for subsequent analysis.
In order to confirm that MAP1LC3Av1 gene expression is regulated by DNA methylation, a de-methylation treatment was performed. De-methylation treatment significantly increased MAP1LC3Av1 mRNA expression (p <0.01) and significantly decreased the locus's methylation level (p <0.01) in the both cell lines compared to untreated cells (Figs. 1d  and 1e ). These results showed that MAP1LC3Av1 was methylation-silenced in gastric cancer cells.
Induction of autophagy in normal rat gastric epithelial cells
MAP1LC3Av1 is expected to be un-methylated and ubiquitously expressed in normal cells because autophagy is essential for normal growth and differentiation in human cells. 26, 28 To investigate the carcinogenic process from normal gastric epithelial cells, we used RGE cells, which correspond to conditionally immortalize normal gastric epithelial cells previously developed from a transgenic rat. 30 As expected, map1lc3a (the rat homolog of the human MAP1LC3Av1 gene) was unmethylated and highly expressed in all three types of RGE cell lines (RGE 1-21, 1-03 and 1-01; Figs. 2a and 2b) . As RGE 1-01 cells formed a monolayer in vitro (data not shown), we selected RGE 1-01 cells for use in subsequent experiments.
H. pylori and cytokines (TNFa and IL6) are known to induce autophagy in gastric epithelial cells, [14] [15] [16] [17] [18] [19] [20] as described in the introduction section. After 12 hrs of incubation TNFa and IL6 can induce autophagy in gastric epithelial cells (Supporting Information Figure 1 ). To analyze the additive effect of H. pylori infection and H. pylori-inducing cytokines (TNFa and IL6) on autophagy, RGE 1-01 cells were co-cultured with H. pylori and stimulated with TNFa, IL6 or Cancer Genetics and Epigenetics the both. Induction of autophagy was assessed by the conversion of the cytosolic LC3 (LC3-I) to auto-phagosomal membrane-associated LC3 (LC3-II) in western blotting. Autophagy was more strongly induced in cells stimulated with H. pylori and the cytokines than in those with H. pylori alone. Furthermore, the combination of TNFa and IL6 has more additive effect on autophagy than each one of them (Figs. 2c and 2d ). These results suggested that H. pylori infection and the following the release of the cytokines could induce autophagy in gastric epithelial cells and could account for carcinogenesis of gastric epithelial cells in in vivo situation.
Autophagy impairment in map1lc3a knock-down cells
Knock-down of map1lc3a was performed with siLC3A in RGE 1-01, and the protein level of map1lc3a successfully decreased to 10% of the control (Figs. 3a and 3b) . Also, we confirmed that the interference-mediated silencing of map1lc3a did not alter the protein expression of map1lc3b gene, the rat homolog of the human MAP1LC3B gene. To analyze the role of map1lc3a in autophagy, RGE 1-01 cells (with or without siLC3A) were infected with patient-derived H. pylori isolate. Autophagy was induced in the control (without siLC3A) cells infected with either of two H. pylori strains (569A and 573A), not but in the knock-down (siLC3A-treated) cells (Figs. 3c and 3d) . Hence, these data showed that map1lc3a, the homolog of the human MAP1L-C3Av1, is required for normal autophagy function in H. pylori-infected gastric epithelial cells.
Increased cell proliferation, migration and invasion of map1lc3a knock-down cells in the starved condition
As autophagy impairment is known to enhance carcinogenesis, 21, 28 we investigated map1lc3a knock-down gastric cells in the starved condition without FBS for possible increases in properties associated with carcinogenesis, including cell proliferation, migration and invasion. A colorimetric assay showed that the rate of cell proliferation (AU/time) of map1lc3a knock-down cells was twice that of the control cells at 48 hrs (p < 0.001, Fig. 4a ).
An in vitro wound-healing assay showed that the wound closure speed (distance/time) of the knock-down cells was significantly increased compared to that of the control cells (p < 0.001 at 12 and 24 hrs post-scratch; Fig. 4b) . Notably, microscopic inspection confirmed that cellular morphology at the leading edge of the scratch was not altered in the knock- In vitro trans-well cell migration and Matrigel invasion assays showed that the knock-down cells migrated significantly faster across the trans-well chamber compared to the control cells. Hence, a greater number of the knock-down cells were seen in the lower chamber at 48 hrs posttransfection (p < 0.001, Fig. 4c) . Similarly, a greater number of the knock-down cells invaded the Matrigel layer compared to the control cells in the same periods of time. At 36 hrs post-transfection, the Matrigel layer contained almost twice the number of the invading knock-down cells as seen with the control cells (p < 0.001, Fig. 4d and Supporting Information Figure 2B ). Figure 3a provide representative image from one of the three independent experiments. MAP1LC3Av1, MAP1LC3A variant 1; siLC3A, siRNA of map1lc3a; siControl, negative control siRNA; *, p < 0.01, Student's t test.
Methylation silencing of MAP1LC3Av1 in human gastric tissues
The frequency of MAP1LC3Av1 methylation silencing was assessed in human gastric tissues, including 5 H. pylori-negative normal tissues and 30 H. pylori-infected paired tissues (gastric cancer tissues and the corresponding non-cancerous tissues). Gastric tissues in which at least 1% of cells exhibited methylation of MAP1LC3Av1 were defined as methylated. Of these methylated tissues, those with the mRNA expression levels less than 1x10 22 /GAPDH (50% less than the mean mRNA expression levels in H. pylori-negative normal gastric tissues) were defined as being methylation-silenced. The qMSP and RT-PCR data showed un-methylation and high expression levels of MAP1LC3Av1 in all of the H. pylori-negative gastric tissues ( Table 1) . Methylation of MAP1LC3Av1 was seen in 50% of H. pylori-infected cancerous mucosae and in 70% of H. pylori-infected non-cancerous mucosae. The methylation silencing was detected in 23.3% of H. pyloriinfected cancerous mucosae and 40% of H. pylori-infected non-cancerous mucosae ( Table 1) .
The frequency of methylation of MAP1LC3Av1 tended to depend on the severity of atrophy (score 0: 0% (0/0), score 1: 50% (7/14), score 2: 67% (6/9), score 3: 100% (3/3), p 5 0.105, Cochran-Armitage trend test) and intestinal metaplasia (50% (5/10), 56% (5/9), 80% (4/5), 100% (2/2), p 5 0.120) according to updated Sydney system. Also, as for methylation-silencing, same trends were observed (atrophy; 0% (0/0), 36% (5/14), 33% (3/9), 100% (3/3), p 5 0.126, intestinal metaplasia; 30% (3/10), 33% (3/9), 60% (3/5), 100% (2/2), p 5 0.062). Thus, the 5 3) . siLC3A, siRNA of map1lc3a; siControl, negative control siRNA; NS, not significant; *, p < 0.01; **, p < 0.001, Student's t test. Table 1 . The frequency of methylation and the methylation silencing of MAP1LC3Av1 in H. pylori-negative or -infected gastric mucosa H. pylori-negative normal mucosa (n 5 5)
Methylation Silenced 0% (0) 40% (12) 23.3% (7) The number in parentheses indicates the number of samples.
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methylation and methylation-silencing might be partially associated with the severity of atrophy and intestinal metaplasia. As the methylation and methylation-silencing has been detected in 30 to 40% of gastric mucosae with mild atrophy or without intestinal metaplasia, the methylation and methylation-silencing would not completely link to the presence of atrophy or intestinal metaplasia and the other mechanisms might contribute to the methylation. Furthermore, immunohistochemistry confirmed that methylation silencing correlated with decreased expression of MAP1LC3Av1 at the protein level. Figure 5 provides a representative example showing that the amount of LC3Av1 protein in methylated cancer tissue was much lesser than that in unmethylated non-cancerous tissue obtained from the same patient (Fig. 5 ). These results suggested that H. pylori infection causes methylation silencing of MAP1LC3Av1 even in non-cancerous mucosae, leading to impairment of autophagy and facilitating progression toward gastric cancer.
Discussion
Autophagy is an essential pathway for maintenance of homeostasis, limiting inflammation, tissue damage and genome instability. 26 H. pylori infection is known to disrupt autophagy in gastric epithelial cells. 22 Many factors might be responsible for H. pylori-induced autophagy inhibition. Here, we demonstrated that MAP1LC3Av1 is frequently methylation-silenced in H. pylori-infected gastric cancerous and non-cancerous mucosae, and showed that MAP1LC3Av1 is regulated by DNA methylation of its promoter region. In addition, knock-down of map1lc3a, the rat homolog of human MAP1LC3Av1 gene, disrupted the autophagy pathway in normal gastric epithelial cells. We presented experimental evidence indicating that methylation silencing of MAP1LC3Av1 is an important cause of the impairment of H. pylori-induced autophagy.
LC3 protein is a known major regulator of autophagosome formation; of the five LC3-encoding genes (MAP1LC3Av1, MAP1LC3Av2, MAP1LC3B, MAP1LC3B2 and MAP1LC3C) identified in humans, LC3B is known to be the most major protein for autophagy. 28 In the recent study by Bai et al. LC3Av1 was shown to co-localize with LC3B in the same autophagosome during starvation-and p53 activation-induced autophagy in a human osteosarcoma cell line. 29 However, they did not assess whether LC3Av1 was essential for autophagy or not by knock-down or restoration of LC3Av1. In the present work, using the LC3A knock-down cells and antibodies specific for LC3Av1 or LC3B, we showed that the presence of LC3Av1 was required for the conversion of LC3B-I to LC3B-II during H. pylori-induced autophagy in gastric epithelial cells, suggesting that LC3Av1 play an essential role in autophagosome formation during H. pylori-induced autophagy. Furthermore, regarding silencing of MAP1LC3Av1, Bai et al. also reported that MAP1LC3Av1 was inactivated in most human cancer cell lines and primary esophageal tumor samples. 29 Additionally, they showed that restoration of LC3Av1 was sufficient to inhibit tumor growth in an esophageal squamous cell carcinoma cell line. As they assessed MAP1LC3Av1 expression in existing cancer cell lines and cancer tissues instead of normal cells, it was unclear whether the methylation silencing of MAP1LC3Av1 had contributed to the process of gastric cancer development induced with H. pylori infection. In the present study, we showed that MAP1LC3Av1 was methylation-silenced in 40% of H. pylori-infected non-cancerous mucosae, showing that methylation silencing of MAP1LC3Av1 correlates with the development of gastric cancer at a pre-cancerous step.
Recently, Castañ-Rodr ıguez et al. reported that the expression of various host Atg genes is modulated by H. pylori infection. 40 They showed that 28 Atg genes, including core Atg genes and Atg regulators, were downregulated in a gastric cancer cell line (AGS) co-cultured with H. pylori on only mRNA expression and they did not analyze epigenetics of Atg genes in relation to H. pylori infection. Also they could not identify the downregulation of MAP1LC3Av1 expression by H. pylori infection, presumably because MAP1LC3Av1 is constitutively methylation-silenced in the established gastric cancer cell line AGS, as we showed in Figures 1b and 1c . Additionally; they did not investigate normal gastric epithelial cells in their experiments. In the present study, we used normal gastric cells, gastric cancer cell lines, gastric tissues from H. pylori-negative subjects and tissue-matched non-cancerous and cancerous mucosa from H. pylori-infected gastric cancer patients. Therefore, our study is expected to provide a wider analysis of the influence of H. pylori infection on the epigenetics of the host genome during early stages of gastric carcinogenesis.
Inactivation of some Atg genes has been previously reported to be related to cancers. Disruption of the human BECN1 gene has been shown to result in impaired autophagy and increased cellular proliferation, thereby contributing to the pathogenesis of various non-gastric cancers, such as prostate, ovarian and breast cancers. 41 Additionally, a decrease of BECN1 expression transforms non-small cell lung carcinoma into a more aggressive neoplasm. 42 However, in the present work, our methylation microarray showed that BECN1 remained un-methylated in H. pylori-negative gastric mucosae and in H. pylori-infected gastric non-cancerous and cancerous mucosae (data not shown). In separate work, Tang et al. reported that overexpression of miRNA30-b in response to H. pylori infection led to inactivation of BECN1 and ATG12, resulting in decrease of host autophagy response and thereby favoring intracellular survival of H. pylori. 24 In confirmation of their model, those authors showed that the knocked-down for BECN1 or ATG12 exhibited increased survival of intracellular H. pylori. However, they showed that autophagy was only partially inhibited in an in vitro model of H. pylori infection. In contrast to the partial inhibition of autophagy by miRNA30-b in a gastric cancer cell line, our results showed complete inhibition of autophagy by methylation-silencing of MAP1LC3Av1 in normal gastric epithelial cells.
Besides inactivation of BECN1 and ATG12, the mutations in several Atg genes were previously reported in relation to the development of cancer. Kang et al. detected the frameshift mutations in ATG2B, ATG5, ATG12 and ATG9B at frequencies of <16% in gastric cancer and <14% in colorectal cancer. 43 However, they did not show any direct effect of these mutations on the expression or function of the corresponding Atg genes. Also, they detected the frameshift mutations in only cancer tissues with high microsatellite instability, but not in noncancerous tissues. Thus, it was unclear whether these cancers were initiated due to these mutations. Three of the genes, ATG2B, ATG5 and ATG12, harbor CGIs in their promoter regions. However, methylation microarray experiment in our study showed that ATG5 and ATG12 were un-methylated in H. pylori-negative gastric mucosae and in H. pylori-infected noncancerous and cancerous mucosae. Additionally, we observed that ATG2B was un-methylated in two gastric cancer cell lines (Fig. 1c) . These results suggested that DNA methylation of these three Atg genes is not associated with H. pylori-induced gastric carcinogenesis.
In humans, H. pylori infection usually occurs during childhood, and persists for the rest of the host's life unless H. pylori is eradicated by antibiotics. H. pylori infection induces the release of cytokines, including TNFa and IL6, from the accumulating inflammatory immune cells in gastric tissues. 14, 15 Both H. pylori and the released cytokines were the inducers of autophagy in gastric epithelial cells in vitro, as we showed in Figures 2c and 2d . Furthermore, there was also an additive effect on the induction of autophagy by these factors. Therefore, the both H. pylori and cytokines could initiate cell damages, such as DNA damages and genome instability, enough to induce autophagy in the gastric epithelial cells. And, the possible cell damages would be avoided by normal autophagy system. The same phenomenon would be seen in the stomach of patients with short-term H. pylori infection. Because autophagy is protective to DNA damage, gastric cancers rarely develop in patients with short-term H. pylori infection. As long-term H. pylori infection is known to induce aberrant DNA methylation at CGIs in the promoter regions of various genes and inactivate the corresponding genes (methylation silencing) in gastric epithelial cells, 12 in patients with long-term H. pylori infection, impairment of autophagy would be expected by methylation silencing of an Atg gene, MAP1LC3Av1. Conversely, the cytokines, such as TNFa and IL6, are known to be continuously released by inflammatory immune cells in the stomach with long-term H. pylori infection. 14, 15, [44] [45] [46] That is, TNFa and IL6 would not be suppressed only by methylation silencing because of the absence of CGIs in the promoter regions of these genes but also by any other suppressive mechanisms during the long-term H. pylori infection. Therefore, the cell damages would be initiated by these cytokines and, however, would not be recovered by autophagy in the stomach with long-term H. pylori infection. In our experiments, MAP1LC3Av1 was frequently methylated and silenced in non-cancerous gastric mucosae of gastric cancer patients with long-term H. pylori infection, as we showed in Table 1 . As the silencing of MAP1LC3Av1 causes a complete inhibition of autophagy, as we showed in the knock-down experiment (Fig. 3c) , H. pylori-induced methylation silencing of MAP1LC3Av1 could cause the accumulation of the cell damages in H. pyloriinfected cells, leading to the carcinogenic transformation and ultimately the development of gastric cancer. Our data showed that 50% of clinical gastric cancer tissues were methylated, and 23.3% of those were methylation-silenced (Table  1) . Therefore, long-term H. pylori infection would disrupt autophagy by the frequent methylation silencing of MAP1L-C3Av1 and accumulate cell damages in the gastric epithelial cells of the patients with long-term H. pylori infection.
In the present study, we performed qMSP and adopted a threshold of 1% for defining a tissue as methylated. This threshold means that the target gene was methylated in at least 1% of the cells in a given specimen. Even if a few cells are methylated, these methylated cells have the potential to developing cancers. Therefore, we emphasize that this threshold of methylation is appropriate for the assessment of an early step of carcinogenesis. Also, the decreases of mRNA expression levels of twofold or more (compared to those in normal gastric tissue) were considered as silencing in the present study. Based on these criteria, we found that 42.9% (9 out of 21) of the methylated H. pylori-infected noncancerous specimens were not silenced, and 53.3% (8 out of 15) of the methylated H. pylori-infected gastric cancer tissue specimens were not silenced. The frequencies of methylation and silencing of MAP1LC3Av1 in H. pylori-infected clinical samples were discrepant because > 1% of methylation level was defined as methylated. The methylated specimens could contain a maximum of 99% un-methylated cells that express MAP1LC3Av1. Therefore, some methylated specimens were not observed as silenced.
In conclusion, we demonstrated that H. pylori-induced methylation silencing of an Atg gene, MAP1LC3Av1, impairs the autophagy pathway known to lead to carcinogenesis in gastric epithelial cells. Additionally, our study provided novel evidence for the clinical significance of MAP1LC3Av1 methylation and expression levels as an early indicator of carcinogenic transformation of non-cancerous mucosae in H. pyloriinfected gastric cancer patients. Furthermore, our data suggested that chemoprevention against gastric cancer induced via H. pylori-associated epigenetic impairment of autophagy can be achieved using de-methylating agents.
